The Medicines and Healthcare products Regulatory Agency (MHRA) has published Drug Safety Update for October 2009 (PDF).
This issue contains a Yellow Card Scheme update that summarises the adverse drug reports that have been submitted in the first year of the human papillomavirus (HPV) immunisation programme.
Hot Topics cover some clinically significant drug-smoking interactions and recent results for aspirin in primary prevention. This latter section reminds clinicians that aspirin is not licensed for primary prevention of thrombotic vascular disease and advises that the balance of benefits and risks should be considered for each individual.
The Stop Press section provides some reassurance for clinicians after a recent cohort study found no clear evidence of an association between varenicline and suicidal behaviour.
Action: Clinicians will find this publication to be a useful review of current issues in drug safety.
|« New glargine cancer questions||Saxagliptin launched »|